{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MOXI&page=13",
    "query": {
      "intervention": "MOXI",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 314,
    "total_pages": 32,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MOXI&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MOXI&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:57:22.013Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02820311",
      "title": "Thorough QT (TQT) Study of TD-4208 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiac Repolarization in Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "TD-4208 175 mcg",
          "type": "DRUG"
        },
        {
          "name": "TD-4208 700 mcg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for TD-4208",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin 400 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2016-05",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02820311"
    },
    {
      "nct_id": "NCT02206204",
      "title": "Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiodynamics",
        "Safety",
        "Tolerability",
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "selexipag",
          "type": "DRUG"
        },
        {
          "name": "placebo for selexipag",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin-matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 159,
      "start_date": "2012-06",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2014-08-01",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02206204"
    },
    {
      "nct_id": "NCT01049022",
      "title": "Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin (Avelox, BAY12-8039)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "3 Months to 14 Years"
      },
      "enrollment_count": 31,
      "start_date": "2010-05",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2015-07-22",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Orange, California • San Diego, California + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01049022"
    },
    {
      "nct_id": "NCT02410772",
      "title": "TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "rifapentine",
          "type": "DRUG"
        },
        {
          "name": "rifapentine and moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 2516,
      "start_date": "2016-01-25",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • New York, New York • Fort Worth, Texas + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02410772"
    },
    {
      "nct_id": "NCT00831961",
      "title": "Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Conjunctival and nasopharyngeal bacteria cultures",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2009-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-09",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00831961"
    },
    {
      "nct_id": "NCT07023029",
      "title": "A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Sickle Cell Disease",
        "Thalassemia"
      ],
      "interventions": [
        {
          "name": "Etavopivat",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 33,
      "start_date": "2025-06-09",
      "completion_date": "2025-09-22",
      "has_results": false,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07023029"
    },
    {
      "nct_id": "NCT07422298",
      "title": "A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BMS-986278",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2026-02-19",
      "completion_date": "2026-06-14",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07422298"
    },
    {
      "nct_id": "NCT01135680",
      "title": "Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Toxicity"
      ],
      "interventions": [
        {
          "name": "HPN-100",
          "type": "DRUG"
        },
        {
          "name": "HPN-100 or Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 98,
      "start_date": "2010-05",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2024-06-20",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01135680"
    },
    {
      "nct_id": "NCT02819908",
      "title": "Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intraocular Lens Associated Postoperative Inflammation"
      ],
      "interventions": [
        {
          "name": "Imprimis Dropless",
          "type": "DRUG"
        },
        {
          "name": "Imprimis Less Drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Center of North Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-09",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2020-03-09",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 1,
      "location_summary": "Panama City, Florida",
      "locations": [
        {
          "city": "Panama City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02819908"
    },
    {
      "nct_id": "NCT04563845",
      "title": "Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3640254",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-11-09",
      "completion_date": "2021-10-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-06",
      "last_synced_at": "2026-11-19T07:57:22.013Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04563845"
    }
  ]
}